AstraZeneca Pharma India Limited (ASTRAZEN) AI Stock Analysis

• Market Cap: ₹203.86B
• Dividend Yield: 0.35%
• Average Volume (3M): 602.00
• Price to Earnings (P/E): 173.1
• Beta (1Y): 0.76
• Revenue Growth: 35.14%
• EPS Growth: 143.11%
• Country: IN
• Employees: 940
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 13.04
• Shares Outstanding: 25,000,000
• 10 Day Avg. Volume: 682
• 30 Day Avg. Volume: 602
• PEG Ratio: -6.48
• Price to Book (P/B): 27.56
• Price to Sales (P/S): 12.37
• P/FCF Ratio: 333.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: ₹8,970.00 ▲(6.38% Upside)
• Action: Upgraded Date: 10/01/25
• Date: Action: Upgraded 10/01/25

AstraZeneca Pharma India Limited's strong financial performance, characterized by consistent revenue growth and solid cash flow management, is the primary driver of its stock score. However, the high P/E ratio suggests the stock may be overvalued, which, along with neutral technical indicators, tempers the overall score.

Positive Factors

Consistent Revenue Growth

Sustained revenue expansion from ₹8,056m to ₹17,162m (2022–2025) and 34.5% revenue growth reflects durable adoption of branded therapies across oncology, CVRM, respiratory and other areas. This indicates scalable commercial reach and portfolio strength that supports mid-term earnings and reinvestment capacity.

Strong Balance Sheet / Low Leverage

Very low financial leverage (D/E 0.05) alongside rising stockholders' equity and a 50.7% equity ratio enhances financial flexibility. A strong equity base reduces solvency risk and supports medium-term capital allocation for launches, commercial investment or opportunistic M&A without heavy reliance on external debt.

Robust Cash Generation

Improved cash conversion with an operating-cash-to-net-income ratio of 0.56 and reported free cash flow metrics signal reliable cash generation. Strong cash flow underpins the company’s ability to fund working capital, support new product rollouts and absorb cyclical pressures without depending on external financing.

Negative Factors

Net Profit Margin Compression

Net profit margin declined markedly (12.3% to 6.7%) driven by rising operating costs. Persistent margin compression reduces retained earnings and free cash over time, limiting the firm's capacity to reinvest in specialty sales, marketing or to expand higher-margin segments across the medium term.

Declining ROE & Rising Liabilities

Return on equity deterioration alongside growing total liabilities signals weakening capital efficiency and rising obligations. If liabilities continue to climb, the company may face constrained flexibility to fund strategic initiatives or defend margins, pressuring long-term shareholder returns.

Dependence on Parent for Product Flow

The business model principally commercializes the parent group’s brands in India, creating structural dependence on AstraZeneca’s pipeline, launch timing and licensing decisions. Limited control over product approvals, supply or portfolio strategy increases execution risk and can cause uneven revenue pacing.

AstraZeneca Pharma India Limited Business Overview & Revenue Model

Company Description

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

How the Company Makes Money

AstraZeneca Pharma India Limited primarily makes money by commercializing (marketing, distributing, and selling) AstraZeneca’s prescription pharmaceutical brands in India. Revenue is mainly generated from domestic sales of branded medicines to healthcare channels such as hospitals, pharmacies/stockists, and institutional/government purchasers, with demand driven by physician prescribing and hospital formulary adoption in its focus therapy areas (notably oncology and chronic disease segments like cardiovascular/renal/metabolic and respiratory). The company’s earnings are influenced by product mix (higher-value specialty medicines vs. primary care products), breadth and uptake of its portfolio (including launches of new therapies approved for the Indian market), and the scale and effectiveness of its sales and distribution network. Where applicable, revenues can also include tender-based or institutional supplies (e.g., to government or large hospital systems). Specific details on manufacturing revenues, export contributions, royalty/transfer-pricing arrangements with the parent group, or named partnership structures are not available from the prompt; null.

AstraZeneca Pharma India Limited Financial Statement Overview

Summary

AstraZeneca Pharma India Limited demonstrates robust financial health with consistent revenue growth and strong cash flow management. The company maintains a stable balance sheet with minimal leverage and a solid equity base. Despite a decrease in net profit margins and return on equity in recent years, the overall financial performance remains commendable, driven by strong operating efficiencies and cash generation capabilities.

Income Statement

AstraZeneca Pharma India Limited has demonstrated a strong revenue growth trajectory with a notable increase in Total Revenue from ₹8,056 million in 2022 to ₹17,162 million in 2025, marking consistent annual growth. The Gross Profit Margin remains robust, improving from 55.6% in 2022 to 43.9% in 2025. EBIT and EBITDA Margins are stable with EBIT Margin at 12.5% and EBITDA Margin at 11.5% in 2025, highlighting operational efficiency. However, the Net Profit Margin decreased from 12.3% in 2024 to 6.7% in 2025 due to rising operational costs.

Balance Sheet

The company maintains a strong equity base with Stockholders' Equity increasing from ₹5,113.9 million in 2022 to ₹7,703.5 million in 2025. The Debt-to-Equity Ratio is low at 0.05 in 2025, indicating low financial leverage. The Equity Ratio improved to 50.7% in 2025, reflecting a stable financial position. However, Total Liabilities have increased over time, which could pose a risk if not managed properly. Return on Equity (ROE) decreased from 22.7% in 2022 to 15.0% in 2025, requiring attention.

Cash Flow

The company exhibits strong cash flow management, with Free Cash Flow growing significantly from ₹911.8 million in 2022 to ₹636.1 million in 2025. The Operating Cash Flow to Net Income Ratio improved to 0.56 in 2025, indicating efficient conversion of income into cash. The company's ability to generate sufficient cash flow to cover its capital expenditures and operating needs is a positive financial indicator.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	20.06B	17.16B	12.96B	10.03B	8.06B	8.09B
Gross Profit	8.80B	7.53B	6.22B	5.78B	4.48B	4.78B
EBITDA	3.16B	1.98B	2.36B	1.51B	1.01B	1.48B
Net Income	1.99B	1.16B	1.62B	992.90M	616.00M	933.00M
Balance Sheet
Total Assets	16.15B	15.18B	10.78B	9.85B	8.57B	7.75B
Cash, Cash Equivalents and Short-Term Investments	4.10B	5.53B	5.06B	5.00B	4.48B	3.52B
Total Debt	347.90M	357.30M	45.90M	72.14M	86.30M	121.40M
Total Liabilities	8.16B	7.48B	3.66B	3.96B	3.45B	3.19B
Stockholders Equity	7.99B	7.70B	7.12B	5.89B	5.11B	4.56B
Cash Flow
Free Cash Flow	-660.20M	636.10M	171.10M	497.70M	911.80M	970.70M
Operating Cash Flow	-657.30M	653.60M	278.70M	582.90M	1.01B	1.05B
Investing Cash Flow	135.40M	308.00M	217.40M	181.10M	47.40M	1.73B
Financing Cash Flow	-845.60M	-655.90M	-443.80M	-244.80M	-94.60M	-89.70M

AstraZeneca Pharma India Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8431.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTRAZEN, the sentiment is Negative. The current price of 8431.7 is below the 20-day moving average (MA) of 8617.76, below the 50-day MA of 8586.95, and below the 200-day MA of 8952.80, indicating a bearish trend. The MACD of -117.88 indicates Positive momentum. The RSI at 31.37 is Neutral, neither overbought nor oversold. The STOCH value of 12.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTRAZEN.

AstraZeneca Pharma India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALKEM	72 Outperform	₹615.23B	25.97	―	0.80%	9.32%	11.25%
ASTRAZEN	70 Outperform	₹203.86B	173.10	―	0.35%	35.14%	143.11%
GLAXO	63 Neutral	₹386.22B	35.44	―	2.16%	4.17%	41.51%
GLENMARK	53 Neutral	₹589.04B	35.61	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%